Small vs Large LDL: What Ron Krauss Says Really Drives Heart Risk
Ron Krauss, who has studied LDL subfractions for decades, explains that small LDL particles carry disproportionate risk because they stick to the artery wall, oxidize more readily and circulate longer. But large LDL are not harmless either: at high enough levels, or when the liver fails to clear them, they also drive plaque. His practical conclusion is that what matters is the amount of each particle type, not the average particle size.
Overview
This long-form conversation walks through one of the most contested questions in lipid science: do all LDL particles carry the same risk, or do the small, dense ones matter more? Krauss starts from the basics — cholesterol does not float freely in blood, it travels inside lipoprotein particles, and it is those particles that deliver cholesterol into the artery wall. He explains why the standard LDL cholesterol test can miss abnormal particle numbers entirely, and why small LDL bind more tightly to the artery wall, oxidize more readily and stay in circulation longer.
He then addresses the counterarguments head-on: the claim that larger particles' bigger cholesterol cargo exactly offsets their lower toxicity, the studies where adjusting for ApoB makes the small-LDL signal vanish, and the limits of Mendelian randomization for tangled metabolic traits. Krauss is candid about measurement problems, criticising one widely used commercial NMR panel as unreliable for LDL subfractions. He also unpacks Lp(a), which hides inside standard particle counts and sits at the larger end of the size range.
On clearance, he argues that high large-LDL levels in lean, healthy people usually reflect impaired receptor uptake and longer residence time rather than a change in the particle itself. Asked whether one should try to make one's LDL bigger, his answer is a flat no — average size is a statistical artefact, concentration is the target. The conversation closes on food: mostly plants, nuts, intact whole kernels, and less processed meat, cream, refined grain and added sugar.
Key quotes
5Some people have interpreted the work that I've done to suggest that large LDL are benign — that's not true.
The small LDL level is embedded in this very complex set of factors which I've called the tangled web of risk factors.
It's not LDL size, it's the amount of LDL of a certain size.
Lp(a) is a particle that looks a lot like an LDL particle — it promotes even greater oxidation than smaller LDL.
Is it worth trying to increase the LDL size? I'll give you a one-word answer: no.
Key ideas
9Cholesterol travels, it doesn't float
Cholesterol is a waxy substance that never circulates alone; it rides inside spherical lipoprotein particles carrying fats and proteins. It is the particle that enters the artery wall, which is why particle-level thinking replaced cholesterol-level thinking.
LDL cholesterol is an imperfect stand-in
The routine LDL-C test measures the cholesterol cargo, not the number of vehicles. Someone can have normal or low LDL-C and still carry an abnormal particle count, and that mismatch is routinely missed in standard screening.
Why small particles behave worse
Small LDL bind more tightly to the artery wall and oxidise far more readily than large ones, and oxidation is the step that triggers inflammation. Their easier entry into the wall, by contrast, is the weakest of the three mechanisms.
The tangled web
Small LDL rarely travels alone; it clusters with abdominal fat, insulin resistance, higher blood pressure and inflammation. That statistical entanglement is what keeps the field from producing clean evidence for small LDL as a standalone target.
Large LDL are not benign
Krauss rejects the reading that large particles are harmless. They carry more cholesterol per particle, so at extreme concentrations — as in familial hypercholesterolemia, where clearance is broken — they clearly drive disease.
The population arithmetic
Isolated high LDL from receptor defects may explain roughly 5% of heart disease cases, while the metabolic-syndrome cluster containing small LDL sits behind an estimated 30-40%. Rising body weight has made the second pattern far more common.
ApoB is powerful but not the whole answer
Krauss calls himself a fan of ApoB: it counts total atherogenic particles and is exceptionally well standardised. His objection is that it cannot tell you whether that elevation comes from small LDL, large LDL or Lp(a) — and those have different drivers.
Measurement quality shapes the debate
He argues that a widely used commercial NMR panel misidentifies the small LDL fraction, and that studies built on it reach flawed conclusions. He also notes that adjusting a curvilinear relationship with linear statistics distorts the result.
Residence time may matter most
Particles that are not cleared by liver receptors circulate longer and get more chances to hit the artery wall. Small LDL are cleared less efficiently; high large-LDL levels in otherwise lean people usually signal a clearance defect rather than a nastier particle.
Practical takeaways
7- 1
Start with waist, weight and movement 5:00
Excess fat around the middle sits upstream of blood pressure, blood sugar and the small-LDL pattern at once. Body composition and activity are the first lever, before any measurement debate.
- 2
Ask about particles, not just cholesterol 12:00
A standard LDL cholesterol number can look reassuring while particle count is elevated. Knowing that a particle-based measure exists is what lets you have a more informed conversation with your clinician.
- 3
Chase concentration, not average size 46:00
The number to watch is how many small particles are in circulation, not the mean diameter. A rising average size only helps if it reflects fewer small particles.
- 4
Lp(a) needs its own measurement 1:10:30
Lp(a) hides inside total particle counts and cannot be separated out by the usual size-based methods. It is measured by a dedicated immunoassay, and Krauss has long argued for including it.
- 5
Build the plate around plants and nuts 1:32:00
The strongest consensus he'll endorse is more plant foods overall, with walnuts and almonds standing out. Most people simply don't eat enough of this category.
- 6
Keep the kernel intact 1:38:00
Once a grain's kernel is cracked, the carbohydrate is absorbed faster, which feeds the insulin-resistance and lipid pattern. Steel-cut oats and dark rye pumpernickel sit near the intact end; fibre grams per package are a useful proxy.
- 7
The short avoid-list 1:36:30
Processed red meat, cream and butter, heavily refined grains and added sugars are the items he flags. Cheese, he notes, is probably less concerning than its reputation suggests.
Topics & chapters
15The one-word answer
A cold open on the question that frames the episode: should you try to make your LDL particles bigger?
What actually causes heart disease
Plaque buildup narrows the vessels feeding the heart and brain. Krauss frames the whole process as something we can intervene on.
Lifestyle first, medication when it fails
Weight, waist circumference, blood pressure and exercise come first. Genetics sometimes overrides them, and that's where medical tools enter.
From cholesterol to lipoproteins
Why the public argument gets stuck on cholesterol while the science moved to the particles that transport it.
Three mechanisms of small LDL
Easier entry, tighter binding and greater oxidation — and which of the three actually holds up.
The tangled web of risk factors
Small LDL travels with insulin resistance, abdominal fat and blood pressure, making clean attribution nearly impossible.
Are large LDL benign? No
Familial hypercholesterolemia as the clearest case where very high large-LDL levels cause disease.
The counterarguments
Rabbit-versus-human entry data, and the claim that bigger cholesterol cargo exactly offsets lower toxicity.
ApoB, LDL-P and what they can't tell you
Both are strong markers of total particle burden, neither identifies which particle type is responsible.
Assay quality and statistics
Krauss's criticism of a widely marketed NMR panel and of linear adjustment applied to curvilinear relationships.
Limits of Mendelian randomization
Genetic markers rarely affect just one trait, which makes clean separation of interwoven metabolic factors difficult.
Lp(a): the hidden particle
How Lp(a) sits at the larger end of the size range, hides inside particle counts, and needs its own immunoassay.
Clearance and residence time
Why lean people with high LDL usually have a clearance defect, and why circulation time may be the dominant factor.
Autopsy data and remnant particles
What electron microscopy of plaque can and cannot tell us, and where remnant lipoproteins fit in.
Foods for heart health
Plants, nuts and intact kernels on one side; processed meat, cream, refined grain and added sugar on the other.